Alpelisib

Alpelisib is a phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor indicated for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. Mediocon Inc supplies pharmaceutical-grade Alpelisib for licensed oncology API manufacturers.

Key Features

• Selective PI3Kα inhibitor
• GMP compliant manufacturing
• Used in breast cancer targeted therapy
• Effective against PIK3CA mutations

Applications

• HR+/HER2- advanced breast cancer
• Combination fulvestrant therapy
• PIK3CA mutation-positive cancer
• Targeted oncology formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings